|
|
| | PNU 100480 Basic information |
| Product Name: | PNU 100480 | | Synonyms: | PNU 100480;(S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide;Sutezolid;(S)-N-((3-(3-fluoro-4-thiomorpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide;(S)-N-((3-(3-fluoro-4-thiomorpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide(WXC06631);PF-02341272;Sutezolid (PNU-100480, PF-02341272);PNU-100480; U-100480; PF-02341272 | | CAS: | 168828-58-8 | | MF: | C16H20FN3O3S | | MW: | 353.41 | | EINECS: | | | Product Categories: | | | Mol File: | 168828-58-8.mol |  |
| | PNU 100480 Chemical Properties |
| Melting point | 186-187°C | | Boiling point | 609.0±55.0 °C(Predicted) | | density | 1.321±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: soluble20mg/mL, clear | | form | powder | | pka | 15.53±0.46(Predicted) | | color | white to beige | | optical activity | [α]/D -8 to -12°, c = 1 in chloroform-d |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 45 |
| | PNU 100480 Usage And Synthesis |
| Description | PNU 100480 is an oxazolidinone antibiotic that is active against multidrug resistant tuberculosis. It inhibits the growth of M. tuberculosis replicating and nonreplicating strains (MIC = ~400 ng/ml for both) and of clinical isolates that are susceptible or resistant to a combination of isoniazid , rifampin (rifampicin; ), ethambutol , and streptomycin (; MICs = ≤0.0625-0.5 mg/L). It also inhibits the growth of P. insidiosum and P. aphanidermatum clinical isolates (MICs = 4-64 μg/ml). PNU 100480 (100 mg/kg per day) decreases the number of colony forming units (CFU) in the lung in a mouse model of systemic nonreplicating M. tuberculosis infection. | | Uses | Sutezolid is an oxazolidinone antibacterial agent analog. Sutezolid is a promising antimycobacterial agent (tuberculostatic). | | Biochem/physiol Actions | Sutezolid (PNU 100480) is an oxazolidinone antimicrobial. Sutezolid inhibits protein synthesis by inhibiting bacterial mRNA translation. Sutezolid is being investigated for the treatment of multiple drug–resistant and extensively drug-resistant tuberculosis. The compound is a less toxic and more potent derivative of linezolid. |
| | PNU 100480 Preparation Products And Raw materials |
|